QIAGEN Cash on Hand 2010-2022 | QGEN

QIAGEN cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • QIAGEN cash on hand for the quarter ending March 31, 2022 was $1.230B, a 55.33% increase year-over-year.
  • QIAGEN cash on hand for 2021 was $1.065B, a 48.94% increase from 2020.
  • QIAGEN cash on hand for 2020 was $0.715B, a 17.49% decline from 2019.
  • QIAGEN cash on hand for 2019 was $0.867B, a 42.07% decline from 2018.
QIAGEN Annual Cash on Hand
(Millions of US $)
2021 $1,065
2020 $715
2019 $867
2018 $1,496
2017 $1,024
2016 $532
2015 $421
2014 $577
2013 $380
2012 $484
2011 $276
2010 $934
2009 $866
QIAGEN Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $1,230
2021-12-31 $1,065
2021-09-30 $957
2021-06-30 $898
2021-03-31 $792
2020-12-31 $715
2020-09-30 $768
2020-06-30 $899
2020-03-31 $903
2019-12-31 $867
2019-09-30 $804
2019-06-30 $932
2019-03-31 $940
2018-12-31 $1,496
2018-09-30 $921
2018-06-30 $900
2018-03-31 $1,014
2017-12-31 $1,024
2017-09-30 $975
2017-06-30 $609
2017-03-31 $273
2016-12-31 $532
2016-09-30 $464
2016-06-30 $406
2016-03-31 $447
2015-12-31 $421
2015-09-30 $432
2015-06-30 $372
2015-03-31 $401
2014-12-31 $577
2014-09-30 $692
2014-06-30 $655
2014-03-31 $678
2013-12-31 $380
2013-09-30 $356
2013-06-30 $373
2013-03-31 $461
2012-12-31 $484
2012-09-30 $311
2012-06-30 $266
2012-03-31 $275
2011-12-31 $276
2011-09-30 $486
2011-06-30 $953
2011-03-31 $939
2010-12-31 $934
2010-09-30 $887
2010-06-30 $918
2010-03-31 $889
2009-12-31 $866
2009-09-30 $861
2009-06-30 $390
2009-03-31 $337
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.865B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00